VLP Therapeutics Appoints Jacob Licht as COO

7/24/17

VLP Therapeutics, LLC, a biotechnology company focusing on the research and development of therapeutic and preventative vaccines and antibody agents, today announced the appointment of Jacob Licht as Chief Operating Officer.

Mr. Licht comes to VLP Therapeutics with nearly 20 years of business development and strategy experience in the biotechnology and specialty pharmaceuticals industry. He joins VLP Therapeutics after 10 years at Emergent BioSolutions, where he most recently served as VP, Corporate Development. At Emergent, Jacob led strategic planning and initiated, executed and integrated several acquisitions and strategic collaborations to grow the Company. As VLP's Chief Operating Officer, he will lead the company's business development, operations and corporate development efforts. Jacob holds a BA from the University of Chicago and an MBA from the Olin Business School at Washington University in St. Louis.

"Jacob has a wide range of relevant business and strategy leadership experience in the vaccine and therapeutics space," said Wataru Akahata, Ph.D., CEO of VLP Therapeutics. "His experience will be crucial as we seek to execute strategic partnerships and raise money to ensure VLP Therapeutics' continued growth. Additionally, his experience will be vital to our growth as we focus our innovative platform on the most promising areas and move products into the clinic."

About VLP Therapeutics

VLP Therapeutics was established in 2012 by seasoned biopharmaceutical veterans with the mission to develop innovative medical treatments which can transform traditional vaccines and targeted antibody therapies to address global unmet medical needs. Its vision is to combat 21st century global public health problems through its revolutionary next generation i-?VLP technology platform. VLP is currently developing preventative and therapeutic vaccines as well as next generation targeted antibody agents to treat cancer, infectious diseases, such as Malaria, Dengue Fever and Zika virus-based diseases, autoimmune and neurological diseases.

About i-? VLP Technology

The human immune system is biologically designed to protect us against disease. The immune system detects foreign objects such as viruses, bacteria or abnormal self-tissues (like cancer cells) in the body, and not only tries to eliminate these foreign objects, but also "memorizes" them so it can protect the body from them in the future. Vaccines utilize the immune system to protect us from various diseases.